Scarica l'app Stockscreener
0.9984
0.16%
-0.0016
Dopo l'orario di chiusura:
.99
-0.0084
-0.84%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.00
Aprire:
$1.01
Volume 24 ore:
2.06M
Relative Volume:
0.38
Capitalizzazione di mercato:
$291.56M
Reddito:
-
Utile/perdita netta:
$-63.08M
Rapporto P/E:
-3.6978
EPS:
-0.27
Flusso di cassa netto:
$-72.53M
1 W Prestazione:
+0.48%
1M Prestazione:
-4.91%
6M Prestazione:
+40.15%
1 anno Prestazione:
-22.00%
Intervallo 1D:
$0.97
$1.01
Intervallo di 1 settimana:
$0.931
$1.02
Portata 52W:
$0.515
$1.40
Ocugen Inc Stock (OCGN) Company Profile
Nome
Ocugen Inc
Settore
Industria
Telefono
484-328-4701
Indirizzo
11 GREAT VALLEY PARKWAY, MALVERN, PA
Confronta OCGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.9984 | 280.01M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-15 | Iniziato | Maxim Group | Buy |
| 2023-03-01 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Iniziato | Mizuho | Buy |
| 2022-06-15 | Ripresa | ROTH Capital | Buy |
| 2022-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Iniziato | Noble Capital Markets | Outperform |
| 2021-06-11 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
Mostra tutto
Ocugen Inc Borsa (OCGN) Ultime notizie
Ocugen Raises $20M in Registered Direct Offering with Warrants for Potential $30M Boost. - AInvest
Ocugen's $20M Funding Move: Strategic Capital Raise or Warning Signal? - AInvest
Ocugen's $20M Raise: A Calculated Gamble in the Gene Therapy Arms Race? - AInvest
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants - Ocugen
Ocugen announces $20M registered direct offering of common stock, warrants - TipRanks
Ocugen's $20M Equity Raise and Warrant Offering: Strategic Capital Move or Dilution Risk? - AInvest
Ocugen raises $20 million in registered direct offering By Investing.com - Investing.com Australia
Ocugen Lands $50M Potential Financing Deal: Janus Henderson Backs Blindness Gene Therapy Pioneer - Stock Titan
Ocugen Highlights Gene Therapy Advances, Strategic Deals in Second Quarter Update - MSN
AAV for the Hereditary Retinal Diseases Clinical Trial Pipeline Analysis Demonstrates 70+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Ocugen Reports Progress in Gene Therapy Trials - TipRanks
Ocugen Releases Second Quarter 2025 Financial Results, Provides Business Update - VisionMonday.com
Ocugen Analyst Ratings: Bullish and Bearish Perspectives Amidst Price Target Changes - AInvest
Ocugen Reaffirms Buy Rating and $7.00 Price Target with Chardan Capital - AInvest
Ocugen, Inc. SEC 10-Q Report - TradingView
Can Ocugen Inc. Rally Enough to Break EvenSector Based Breakout Stock Forecast Issued - metal.it
How volatile is Ocugen Inc. stock compared to the marketExplosive wealth accumulation - Jammu Links News
What are the latest earnings results for Ocugen Inc.Accelerated financial growth - Jammu Links News
What makes Ocugen Inc. stock price move sharplyExceptional market positioning - Jammu Links News
Is Ocugen Inc. stock overvalued or undervaluedMaximize your gains with professional insights - Jammu Links News
What are analysts’ price targets for Ocugen Inc. in the next 12 monthsGet real-time alerts on high-potential stocks - Jammu Links News
Should I hold or sell Ocugen Inc. stock in 2025Build a diversified portfolio for risk management - Jammu Links News
What institutional investors are buying Ocugen Inc. stockFree Stock Market Real-Time Monitoring - Jammu Links News
Ocugen Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
What are the technical indicators suggesting about Ocugen Inc.Free Stock Market Mentorship - Jammu Links News
Is it the right time to buy Ocugen Inc. stockSuperior returns - Jammu Links News
What are Ocugen Inc. company’s key revenue driversGet alerts on the hottest stocks daily - Jammu Links News
What catalysts could drive Ocugen Inc. stock higher in 2025Unstoppable trading performance - Jammu Links News
What markets is GWH.WS expanding into Is Ocugen Inc. stock a good long term investment option - Jammu Links News
Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years - MSN
Ocugen outlines three licensing applications and 2026 commercialization plans while advancing gene therapy trials - MSN
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates - MSN
Evaluating Ocugen's Q2 Earnings and Strategic Progress: Clinical Milestones and Capital Efficiency as Catalysts for Long-Term Value Creation in Biotech Investing - AInvest
Ocugen Advances Gene Therapy for Blindness with Strategic Deals and Clinical Progress - AInvest
Ocugen Q2 Revenue Surpasses Expectations, Advances Gene Therapy Trials - AInvest
Ocugen, Inc. (OCGN): A High-Risk, High-Reward Biotech Play in Gene Therapy - AInvest
Ocugen, Inc. (NASDAQ:OCGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Ocugen Inc (OCGN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Ocugen Inc’s Earnings Call: Progress Amid Financial Challenges - MSN
Ocugen: Q2 Earnings Snapshot - Chron
Ocugen Provides Business Update with Second Quarter 2025 Financial Results - ADVFN Brasil
Ocugen's Strategic Path to 2026 BLA Filings and Global Gene Therapy Leadership - AInvest
Ocugen's Q2 2025 Earnings Call: Unpacking Contradictions in Trial Timelines, Manufacturing, and Strategic Direction - AInvest
Is Ocugen Inc. a growth stock or a value stockFree Stock Growth Plan For Smart Trading - Jammu Links News
Ocugen shares fall 5.83% intraday after mixed Q2 2025 earnings call and business update. - AInvest
Ocugen’s Revenue Surprised And Analysts Still See Room To Grow - Finimize
Ocugen Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ocugen Inc Azioni (OCGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
3.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):